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ess: tarja.saaresranta@Summary Study objectives: To test the clinical observations that patients with
chronic obstructive pulmonary disease (COPD) have impaired sleep quality without
excessive daytime sleepiness (EDS), and to analyse the aetiological factors.
Participants: Fifteen non-diabetic postmenopausal women with moderate to
severe COPD and 20 community dwelling age-matched control women.
Measurements and results: Patients completed questionnaires, had a polysomno-
graphy and blood tests. Controls filled in the questionnaires. In the Basic Nordic
Sleep Questionnaire, the average (7SD) scores for sleepiness (9.973.0 in patients vs.
7.673.2 in controls, P ¼ 0:025; test range 4–20) and insomnia (18.373.4 vs.
16.674.4, P ¼ 123; test range 7–35) were low. Although 53% had a good night’s sleep
seldom or never and 70% slept restlessly, only 33% felt tired in the mornings. Controls
reported better sleep quality, less tiredness and sleepiness. With polysomnography,
the total sleep time was 4 h 41min 71 h 20min in patients. Sleep was fragmented,
the proportion of stage 1 sleep high and rapid eye movement (REM) latency delayed.
Sleepiness correlated with fasting serum insulin levels (r ¼ 0:59; P ¼ 0:027) and body
movements (r ¼ 0:52; P ¼ 0:047). In stepwise linear regression analyses, sleepiness
was positively associated with insulin levels (P ¼ 0:025) but not with body
movements. Insulin explained 38.0% of the variance in the sleepiness score, when
adjusted for body mass index (BMI).Elsevier Ltd. All rights reserved.
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Sleep quality, sleepiness and fasting insulin in COPD 857Conclusions: Despite short and fragmented sleep, non-diabetic patients with
COPD did not have marked EDS. An association between fasting insulin and sleepiness
suggests that insulin resistance is involved in EDS.
& 2004 Elsevier Ltd. All rights reserved.Table 1 Demographic and respiratory data ofIntroduction
Sleep quality is impaired in patients with chronic
obstructive pulmonary disease (COPD).1–3 Sleep
fragmentation and arousals frequently occur during
events of desaturation.2,4 Fragmented sleep and
frequent arousals lead to daytime sleepiness both
in healthy normal volunteers5 and in patients with
sleep-disordered breathing.6,7 The scarce data
regarding daytime sleepiness in patients with COPD
is contradictory.1,8 According to our clinical ob-
servations, patients with moderate to severe COPD
without acute exacerbation do not complain about
excessive daytime sleepiness (EDS) as patients with
obstructive sleep apnoea syndrome (OSAS) do.
Our aim was to test the hypothesis that ambu-
latory patients with moderate to severe COPD have
impaired sleep quality but do not report EDS. We
also aimed to analyse the possible aetiological
factors. Therefore, we investigated subjective
sleepiness, subjective and objective sleep quality,
nocturnal arterial oxygen saturation and transcu-
taneous partial carbon dioxide pressure in women
with COPD. Because plasma insulin levels are higher
in patients with OSAS than in obese controls
possibly due to hypoxia-related nocturnal increases
in sympathetic activity,9 we also investigated
relationships between serum fasting insulin levels
and the above-mentioned variables.patients.
Patient characteristics,
n ¼ 15
Mean7SD or
median (range)
Age (years) 67.576.0
BMI (kg/m2) 26.974.9
FEV1 (L) 0.73 (0.25–1.8)
FVC (L) 1.370.45
FEV1 (%) 36712
FVC (%) 46716
FEV% 63714
Mean SaO2 during sleep (%) 88.679.4
Nadir SaO2 during sleep (%) 84.8 (46.8–90.1)
Mean tcCO2 during sleep (kPa) 6.371.2
Data presented as mean7SD or median (range). BMI, body
mass index, FEV1, forced expiratory volume in one
second, FVC, forced vital capacity, FEV1(%), forced
expiratory volume in one second percent of predicted
value, FVC (%), forced vital capacity percent of predicted
value, FEV%, 100 (FEV1/FVC), SaO2, arterial oxyhaemo-
globin saturation, tcCO2, transcutaneous carbon dioxide
partial pressure.Participants and methods
Patient selection
We recruited 15 postmenopausal women with
COPD, one of them also presenting with a marked
restrictive component of ventilatory impairment.
The study population comprised of consecutive
female patients visiting at our outpatient clinic in
the department of pulmonary medicine and ful-
filling the study criteria. Demographic and respira-
tory characteristics of the patients are presented in
Table 1. Patients with forced expiratory volume in
one second (FEV1) less than 65% of predicted value,
and a history of episodic or constant daytime
hypoxaemia (PaO2o10.0 kPa) and/or hypercapnia
(PaCO246.0 kPa) assessed by arterial blood gas
analyses were included. All patients were on anoptimal medication and had been in a stable
clinical condition for at least a month prior the
study. Only current non-smokers were included in
order to avoid the effect of smoking and nicotine on
sleep, control of breathing and other factors. Ten
patients were former smokers. Two of them had
quitted smoking at least 6 months but less than one
year before the present study. The others had
stopped smoking 4–27 years before the study. Two
out of five life-long non-smokers had alpha-1-
antitrypsin deficiency. The other three non-smokers
had been exposed for passive smoking and one of
them also had work-related exposure for irritants
more than 10 years likely to contribute to COPD.
The mean of pack-years was 8.8 years (range 0–50).
The postmenopausal status was verified by an
increase in serum concentration of follicle-stimu-
lating hormone over 30 IU/L. None of the patients
had hot flushes or other menopausal symptoms.
The exclusion criteria were heart diseases (ex-
cept cor pulmonale), malignancies, psychiatric,
and neurological diseases, diabetes mellitus, urae-
mia, untreated hypothyroidism, current smoking,
long-term oxygen therapy, use of postmenopausal
hormone replacement therapy, and use of any
medication likely to influence sleep or vigilance
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antidepressants.Controls
For the purpose of the study, questionnaire data
were also collected from 20 postmenopausal con-
trols matched for age (mean age7SD 67.573.4
years). All controls were community dwelling
females without self-reported or doctor-diagnosed
COPD or OSAS.
Each participant gave her written informed
consent. The study protocol was approved by the
Joint Commission on Ethics of Turku University and
Turku University Central Hospital.Measurements
In the evening prior the sleep study, patients
were interviewed and a routine physical examina-
tion was performed. Since neither patients nor
controls had tendency to doze off involuntarily, the
Basic Nordic Sleep Questionnaire10 was preferred to
the Epworth Sleepiness Scale, which focuses on the
probability of falling asleep in various situations.11
The Basic Nordic Sleep Questionnaire surveys
perception of usual sleep quality, sleep latency,
and the number of awakenings per night and naps
per day. Each patient also rated a 10-cm visual
analogue scale (VAS) with a statement ‘‘I am happy
with my sleep quality’’, score ¼ 0 indicating ‘‘com-
pletely agree’’ and score ¼ 10 indicating ‘‘comple-
tely disagree’’. Frequency of morning headaches
was inquired. Sleepiness was assessed by four
questions and insomnia by seven questions adapted
from the Basic Nordic Sleep Questionnaire.10
Sleepiness scores range from 4 to 20 points,
insomnia scores from 7 to 35, the higher scores
indicating more problems with sleepiness or in-
somnia.
In the morning after the sleep study, all patients
completed a 14-item questionnaire relating to their
perceptions of the preceding night’s sleep. This
questionnaire allowed the comparison of subjective
and objective sleep quality. Questions were related
to initiation and maintenance of sleep (for exam-
ple, perceptions of sleep latency, frequency of
arousals), events during sleep (for example, rest-
lessness), sleep-related daytime symptoms (for
example, naps), and issues possibly disturbing sleep
(for example, dyspnoea, sweating). Patients com-
pleted all questionnaires in the presence of one of
the investigators.
An overnight polysomnography included monitor-
ing of electroencephalogram (EEG; C3/A2 and C4/A1), electro-oculogram, and submental electro-
myogram. Arterial oxyhemoglobin saturation (SaO2)
was measured with pulse oximeter using a finger
probe (Ohmeda Biox 3700 Pulse Oximeter, BOC
Health Care, USA). Transcutaneous partial carbon
dioxide pressure (tcCO2) was measured with TCM3
device (TINAsTranscutaneous PO2/PCO2 Monitoring
System, Radiometer, Copenhagen, Denmark). The
sensor was heated up to 43 1C. Movements during
sleep were monitored with a static-charge-sensi-
tive bed.12–14 Quantitative movement analysis,
SaO2 analysis, and carbon dioxide partial pressure
analyses were determined with analyse modules
(UniPlots, Unesta, Turku, Finland). The presence
of airflow was determined via nasal prongs con-
nected to continuous positive airway pressure
device used in diagnostic mode (Sullivan Autosets,
ResCare Limited, Sydney, Australia). Biosignals
were recorded and saved on a PC hard disk using
UniPlot software (UniPlots, Unesta, Turku, Fin-
land) with sampling frequency of 250Hz per
channel and with y-resolution of 12 bytes.
Sleep stages were scored according to standard
criteria15 and expressed as percentage of total
sleep time. Sleep efficiency was defined as percen-
tage of sleep during the sleep period time. Arousal
was defined as an appearance of EEG-alpha activity
for longer than 3 s.16
In the morning after a sleep study, flow-volume
spirometry (Vitalograph Compact II, Vitalograph
Ltd, Buckingham, England) was assessed and blood
samples were collected between 7 and 9 a.m. after
an overnight fast. Serum fasting insulin was
determined with a Phadesephs Insulin RIA kit
(Pharmacia, Uppsala, Sweden).
Controls completed the Basic Nordic Sleep Ques-
tionnaire but did not have sleep studies or blood
tests.Statistical analyses
Pearson correlation coefficients were used in
parametric cases and Spearman correlation coeffi-
cients in non-parametric cases to assess the
association between two numeric measurements.
Linear regression analysis was used to evaluate the
associations between insulin and several variables
or sleepiness and other variables. Body mass index
(BMI) was entered into the stepwise linear regres-
sion analysis model. Wilcoxon test was used in
between group comparisons. Data is presented as
mean7SD when applicable or median (range). In all
tests, Po0:05 was considered significant. Statisti-
cal computing was performed with SAS statistical
package (version 8.01, SAS Institute, Cary, NC).
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Patients were hypoxaemic and their average of
tcCO2 was 6.371.2 kPa during sleep compatible
with COPD (Table 1).Overall subjective sleep quality
Basic Nordic Sleep Questionnaire: In patients
with COPD, the average of sleepiness score of the
Basic Nordic Sleep Questionnaire (9.973.0, test
range 4–20) was low although higher than in
controls (7.673.2, P ¼ 0:025). The averages of
the insomnia scores (18.373.4 vs. 16.674.4, test
range 7–35) did not differ ðP ¼ 0:123Þ: A good
night’s sleep seldom or never was reported by 53%
of the patients and by 10% of controls ðP ¼ 0:006Þ:
Restless sleep was reported by 73% vs. 15%
ðPo0:001Þ and feeling tired every or almost every
morning by 33% vs. 5% ðP ¼ 0:032Þ: Neither patients
nor controls had tendency to doze off involuntarily.
The frequency of morning headaches did not differ
between the groups. Four out of 15 (27%) patients
and 2 out of 20 controls (10%) had morning
headaches ðP ¼ 0:211Þ: Detailed data is presented
in Fig. 1.
VAS: Patients were moderately satisfied with
their subjective sleep quality when measured with
a VAS (mean score 4.073.3). Subjective sleep
quality correlated with forced expiratory volume
(Pearson r ¼ 0:64; P ¼ 0:014).0 20
Naps more frequently than
6 per week
Naps more frequently than
once a week
Awakenings more frequently
than twice during night
Restless sleep usually
Sleep latency shorter than
20 min
Good night's sleep seldom
or never
Tired in the morning less
frequently than once a week
Tired every morning or
almost every morning
Tired every day or almost
every day
Perc
 p<0.001
 p=0.032
 p=0.006
Figure 1 Subjective sleepiness and sleep quality, n ¼ 15 f
(COPD) and n ¼ 20 for age- and gender-matched contro
Questionnaire.10 Data are presented as percentage of subjecSubjective sleep quality during the study
night
Patients reported that they fell asleep rather
soon, slept moderately well, slept as usual, had
some nocturnal movements, woke up several times
during night, woke up earlier than usual, but felt
rather alert in the morning after their sleep study.
Five out of 15 patients reported having naps during
the preceding day. They had no specific complaints
(pains, cough, etc.) disturbing their sleep.Objective sleep quality during the study
night
During the study night, the mean total sleep time
was less than 5 h and sleep efficiency was poor
(Table 2). The proportion of stage 1 sleep was high.
Rapid eye movement (REM) latency was delayed.
Sleep was fragmented (Fig. 2) but EEG arousal
index was low. Total sleep time correlated with
sleep efficiency (Pearson r ¼ 0:94; Po0:0001) as
expected. Any of the variables of overnight sleep
recording did not correlate with spirometric re-
sults.Sleepiness and fasting insulin concentrations
One serum sample was missing and therefore
serum insulin concentrations were assessed only
in 14 patients. None of the patients had dia-
betes mellitus. Their mean fasting serum insulin40 60 80 100
entage of Subjects
Controls
COPD
 p=0.056
or patients with chronic obstructive pulmonary disease
ls. Data were derived from the Basic Nordic Sleep
ts.
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Table 2 Sleep recording data.
Objective sleep quality, n ¼ 15
TST (min) 281780
Sleep efficiency (%) 70.0 (32.7–91.3)
WASO (% of sleep period time) 31.3 (4.5–62.8)
Arousal index (# per hour) 1.0 (0.2–11.4)
BM per hour of sleep 6.3 (1.0–116.6)
MA per hour of sleep 9.576.9
S1 latency (min) 11.5 (2.5–90.5)
S2 latency (min) 22.0 (11.0–144.5)
SWS latency (min) 34.5 (1–220)
REM latency (min) 138 (62.5–285.5)
Stage S1 sleep (% of TST) 26.3 (10.0–88.0)
Stage S2 sleep (% of TST) 28.2714.7
SWS (% of TST) 25.279.8
REM sleep (% of TST) 12.279.2
Stage shifts 16.974.0
Data presented as mean7SD or median (range). BM, body
movements, MA, movement arousals, REM, rapid eye
movements, SWS, slow wave sleep (sleep stages 3 and 4),
TST, total sleep time, WASO, wakefulness after sleep
onset.
Figure 2 Hypnograms of all the 15 patients. Their sleep struc
rapid eye movement sleep, S1, sleep stage 1, S2, sleep stage
T. Saaresranta et al.860concentration was 12.074.2mU/L (reference
range 5–20mU/L, interassay coefficient of varia-
tion 4.6% at control sample level of 12.4mU/L).
One patient had her insulin level above the upper
limit of reference ranges, the value being 22mU/L.
In univariate analyses, sleepiness score corre-
lated with insulin levels (Pearson r ¼ 0:59; P ¼
0:027; Fig. 3) and body movements (Pearson r ¼
0:52; P ¼ 0:047). Sleepiness score or insulin levels
did not correlate significantly with age, BMI, lung
volumes, apnoea-hypopnoea index, insomnia score,
being tired in the morning or with VAS score of the
subjective sleep quality or any measures of the
objective sleep quality except that insulin corre-
lated with percentage of time spent in stage 2 sleep
(Pearson r ¼ 0:53; P ¼ 0:047). When adjusted for
age and BMI, there tended to be positive associa-
tions in linear regression analyses between insulin
and SaO2nadir during sleep overall ðP ¼ 0:086Þ and
during slow wave sleep (SWS; P ¼ 0:091), between
insulin and SaO2mean during stage 2 ðP ¼ 0:050Þ
and stage 4 sleep ðP ¼ 0:058Þ; and between insulinture is remarkably destroyed. MT, movement time, REM,
2, S3, sleep stage 3, S4, sleep stage 4.
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Figure 3 Association between sleepiness score and
serum fasting insulin concentration in postmenopausal
women with chronic obstructive pulmonary disease
(n ¼ 14; Pearson r ¼ 0:59; P ¼ 0:027). Test range for
sleepiness score is 4–20.
Sleep quality, sleepiness and fasting insulin in COPD 861and tcCO2 during sleep overall ðP ¼ 0:052Þ; during
stage 1 sleep ðP ¼ 0:057Þ and during SWS ðP ¼
0:056Þ:
In stepwise linear regression analyses with BMI
entered into the model, sleepiness was positively
associated with insulin levels ðP ¼ 0:029Þ; but not
with body movements ðP ¼ 0:151Þ: Insulin level
explained 38.0% of the variance in the sleepiness
score. BMI did not explain the variance in the
sleepiness score (6.2%, P ¼ 0:434). Insulin level was
positively associated with percentage of stage 2 sleep
ðP ¼ 0:005Þ and with sleepiness ðP ¼ 0:004Þ: Percen-
tage of stage 2 sleep explained 29.0% and sleepiness
47.6% of the variance in the insulin levels. BMI tended
to explain insulin levels (25.4%, P ¼ 0:095). Previous
smoking (pack-years) did not explain sleepiness ðP ¼
0:149Þ or insulin levels ðP ¼ 0:496Þ:Discussion
Our postmenopausal women with moderate to
severe COPD and with mean total sleep time less
than 5 h did not have major daytime sleepiness
although felt somewhat tired. None of our patients
was diabetic and only one had slightly increased
fasting concentration of serum insulin. However,
sleepiness was associated with fasting insulin levels
but not with nocturnal hypoxaemia, arousals, or
sleep fragmentation, which are the conventional
predictors of EDS in healthy subjects or patients
with obstructive sleep apnoea.7,17,18 The results
suggest that chronic lung disease modifies the
pathophysiology of EDS.Objective sleep quality in COPD
The objectively verified poor sleep quality (short
total sleep time, sleep fragmentation, remarkablylittle deep sleep) and lack of EDS is contradictory to
observations in healthy subjects, in whom partial or
total sleep deprivation for one night19 or for
consecutive nights20 results in increased daytime
sleepiness. We were neither able to confirm the
observations that number of EEG arousals, shifts
from other sleep stages to stage 1 sleep or wake,
nor the percentage of stage 1 sleep correlates with
daytime sleepiness.21 In our patients, number of
EEG arousals was low but stage shifts were
frequent, and the percentage time spent awake
or in stage 1 sleep was high. The differences in
study populations between our study (females with
COPD) and that of Stepanski and co-workers21
(patients with sleep apnoea, with periodic leg
movements or with insomnia and healthy volun-
teers without sleep complaints) may explain the
discrepancy.
On the other hand, our findings are in line with
those of Orr and co-workers, who did not observe
any significant daytime sleepiness in male patients
with COPD.8 Despite short total sleep times (mean
4.3 h), their multiple sleep latency test (MSLT)
results were within normal range. Similar total
sleep times (mean 4.7 h) were observed by us but
we did not perform MSLT. However, the rather long
sleep latencies of our COPD patients would predict
normal MSLT results, since the sleep latencies at
night and during MSLT correlate positively.18
The short total sleep time in our patients falls in
previously reported ranges from 3.5 to 4.7 h per
night in COPD1,2,8 However, the total sleep time
was markedly shorter than in healthy elderly
subjects in previous studies19,22,23 or 7.070.6 h
reported by our controls. The percentage of
wakefulness after sleep onset was higher than that
in patients with COPD of Fleetham and co-workers2
or in healthy postmenopausal women (mean age
56.3 years)24 but similar to that of Cormick and co-
authors. Because our patients spent most of the
time in light sleep, arousals easily resulted in
awakenings and thereby in lower arousal index than
previously reported in healthy elderly people19 or
in patients with COPD.1,2 The number of sleep-
stage shifts per hour of sleep was high but is
compatible with previous reports.1,2 Sleep latency
was comparable to those reported previously in the
elderly people19,22,23 or in our controls.
The percentage of sleep stage 1 was high and
the percentage of REM sleep low consistent
with previous observations in the elderly
subjects,19,22,23 or in patients with COPD.1,2
Although the absolute time spent in slow wave
sleep (SWS) or REM was very short, the percentage
time did not differ from that of healthy elderly
people.22,23
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between objective sleep quality and pulmonary
function tests or SaO2 or tcCO2 during sleep. This
finding is consistent with a previous report that the
extent of sleep disruption does not depend on
hypoxaemia and is present also in normoxic
patients with COPD.3Subjective sleep quality and sleepiness
Patients reported to have a good night’s sleep
hardly ever and their sleep was restless. Surpris-
ingly, they were satisfied with their overall sleep
quality measured with VAS. Adaptation to poor
sleep quality could explain this discrepancy. When
asked with a more specified question, they re-
ported poor sleep although failed to report that in a
context of a more general question. Napping is
common among retired elderly people. It was also
quite frequent in our study population and tended
to be more frequent than in controls. It is also
remarkable that in the morning patients felt
relatively alert despite their objectively poor
sleep. Although patients with chronic pulmonary
disease had fatigue, they did not have a compulsory
tendency to fall asleep like patients with OSAS.Insulin and sleepiness
Because sleep or respiratory variables did not
give any explanation to the paradoxical finding of
lack of sleepiness in the presence of poor sleep
quality, it led us to seek other alternatives. Both
obesity25 and hypercytokinemia9,26 have been
linked with EDS. Typical for an advanced chronic
pulmonary disease, our patients were non-obese,
which might explain the lack of daytime sleepiness.
However, sleepiness scores did not correlate with
BMI. We did not measure cytokines. However,
increased circulating levels of tumour necrosis
factor-alpha and interleukin-6 have been reported
in patients with COPD.27 These cytokines are also
known as sleep-promoting cytokines. Therefore, it
is unlikely that different cytokine profiles in sleepy
patients with OSAS and non-sleepy patients with
COPD could explain the difference in their grade of
alertness.
Insulin resistance is common in OSAS.9 Data from
both animal and human studies support an associa-
tion between insulin levels and sleepiness. In rats,
exogenous systemic administration of insulin pro-
motes non-REM sleep but has little, if any effect on
REM sleep.28 Continuous intracerebroventricular
infusion of insulin increases somnolence in rhesus
monkeys.29 Plasma insulin levels are associatedwith postprandial sleepiness in healthy female and
male volunteers.30 Fasting insulin reflects quite
reliably insulin resistance.31 Patients with sleep
apnoea have higher fasting plasma insulin levels
than BMI-matched obese controls.9
There are two major differences between pa-
tients with COPD and OSAS, which may affect
insulin levels. First, patients with OSAS are often
obese and obesity is a well-known risk factor for
insulin resistance.32 Second, in OSAS the changes in
nocturnal oxygen saturation are abrupt while in
COPD they usually are more shallow and constant,
which may enable a better adjustment of body
homeostasis.Limitations of the study
We acknowledge several limitations of our study
design. First, we did not have an adaptation night
for being monitored in a sleep laboratory. However,
our findings of objective sleep quality are consis-
tent with previous studies in patients with
COPD.1,2,8 Patients also reported that they slept
during the study night as usual. Therefore, any
major bias due to possible first night effect seems
unlikely. Second, our control group did not have
sleep studies, blood tests or pulmonary function
tests. However, these issues are unlikely to dis-
prove our major finding of absence of EDS in our
study population. Although the absence of COPD in
controls was based on questionnaire data, it is not
plausible that any of them would have undiagnosed
moderate to severe COPD like our patients. Third,
the number of study participants is small and all are
females. On the other hand, the fact that all the
patients are women may stabilize the observations.
Significant findings even in this small population
suggest strong association.Conclusions
Our non-diabetic patients with moderate to
severe COPD had a remarkably short total sleep
time and fragmented sleep, but did not have major
EDS although had fatigue to some extent. An
association between fasting serum insulin level
and sleepiness suggests that insulin resistance may
play a role in EDS. Lack of insulin resistance may
therefore explain absence of EDS in most patients
with COPD. Whether the observed correlation
between fasting insulin levels and EDS would also
be extrapolated to males, younger patients with
COPD or those with more severe degrees of EDS in
obese patients with diabetes mellitus or with OSAS,
remains to be elucidated.
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